Login Register Cart 0
Review Article

心力衰竭患者的治疗:关注新的药物和设备选择

卷 27, 期 27, 2020

页: [4522 - 4535] 页: 14

弟呕挨: 10.2174/0929867326666190523083747

价格: $65

摘要

心衰(HF)患者的住院率和生存率已得到改善。然而，5年死亡率仍然很高，而且由于人口老龄化和其他急性和慢性心血管疾病的诊断和治疗进展，该病的患病率正在上升。在过去的三十年中，随着针对神经激素激活的药物和防止心源性猝死和改善心脏同步的装置的发展，心力衰竭的治疗设备有了实质性的改善。近年来，抑制血管紧张素受体和新溶血素以及调节f电流的窦房起搏器被发现是提高HF住院率和/或死亡率的安全有效的策略。抗糖尿病药物抑制钠-葡萄糖协同转运体2，导致利钠和渗透性利尿，并可能进一步改善HF的相关结果。此外，心肌肌球蛋白激活剂、可溶性冠苷酸环化酶刺激剂和非甾体类矿皮质激素受体拮抗剂等新兴疗法正在心力衰竭患者的II期和III期研究中接受研究。最后，随着第二代和第三代连续血流左心室辅助装置在临床实践中的应用，先进心衰的治疗得到了迅速发展。正在进行的临床研究将验证新出现的治疗策略在以往临床试验中缺乏代表性的HF人群中的安全性和有效性。

关键词: 心衰(HF)，尼泊尔碱抑制剂，ivabradin，左心室辅助装置，新的治疗策略，窦房起搏。

« Previous Next »
[1]
Mozaffarian, D.; Benjamin, E.J.; Go, A.S.; Arnett, D.K.; Blaha, M.J.; Cushman, M.; Das, S.R.; de Ferranti, S.; Després, J.P.; Fullerton, H.J.; Howard, V.J.; Huffman, M.D.; Isasi, C.R.; Jiménez, M.C.; Judd, S.E.; Kissela, B.M.; Lichtman, J.H.; Lisabeth, L.D.; Liu, S.; Mackey, R.H.; Magid, D.J.; McGuire, D.K.; Mohler, E.R., III; Moy, C.S.; Muntner, P.; Mussolino, M.E.; Nasir, K.; Neumar, R.W.; Nichol, G.; Palaniappan, L.; Pandey, D.K.; Reeves, M.J.; Rodriguez, C.J.; Rosamond, W.; Sorlie, P.D.; Stein, J.; Towfighi, A.; Turan, T.N.; Virani, S.S.; Woo, D.; Yeh, R.W.; Turner, M.B. American Heart Association Statistics Committee;Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation, 2016, 133(4), e38-e360.
[http://dx.doi.org/10.1161/CIR.0000000000000350] [PMID: 26673558]
[2]
Heidenreich, P.A.; Albert, N.M.; Allen, L.A.; Bluemke, D.A.; Butler, J.; Fonarow, G.C.; Ikonomidis, J.S.; Khavjou, O.; Konstam, M.A.; Maddox, T.M.; Nichol, G.; Pham, M.; Piña, I.L.; Trogdon, J.G. American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American heart association. Circ. Heart Fail, 2013, 6(3), 606-619.
[http://dx.doi.org/10.1161/HHF.0b013e318291329a] [PMID: 23616602]
[3]
Gerber, Y.; Weston, S.A.; Redfield, M.M.; Chamberlain, A.M.; Manemann, S.M.; Jiang, R.; Killian, J.M.; Roger, V.L. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern. Med., 2015, 175(6), 996-1004.
[http://dx.doi.org/10.1001/jamainternmed.2015.0924] [PMID: 25895156]
[4]
Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr; Drazner, M.H.; Fonarow, G.C.; Geraci, S.A.; Horwich, T.; Januzzi, J.L.; Johnson, M.R.; Kasper, E.K.; Levy, W.C.; Masoudi, F.A.; McBride, P.E.; McMurray, J.J.; Mitchell, J.E.; Peterson, P.N.; Riegel, B.; Sam, F.; Stevenson, L.W.; Tang, W.H.; Tsai, E.J.; Wilkoff, B.L. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 2013, 128(16), 1810-1852.
[http://dx.doi.org/10.1161/CIR.0b013e31829e8807] [PMID: 23741057]
[5]
Movsesian, M.; Stehlik, J.; Vandeput, F.; Bristow, M.R. Phosphodiesterase inhibition in heart failure. Heart Fail. Rev., 2009, 14(4), 255-263.
[http://dx.doi.org/10.1007/s10741-008-9130-x] [PMID: 19096931]
[6]
Starling, R.C.; Estep, J.D.; Horstmanshof, D.A.; Milano, C.A.; Stehlik, J.; Shah, K.B.; Bruckner, B.A.; Lee, S.; Long, J.W.; Selzman, C.H.; Kasirajan, V.; Haas, D.C.; Boyle, A.J.; Chuang, J.; Farrar, D.J.; Rogers, J.G. ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results. JACC Heart Fail., 2017, 5(7), 518-527.
[http://dx.doi.org/10.1016/j.jchf.2017.02.016] [PMID: 28396040]
[7]
McMurray, J.J.; Packer, M.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.; Shi, V.C.; Solomon, S.D.; Swedberg, K.; Zile, M.R. PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur. J. Heart Fail., 2013, 15(9), 1062-1073.
[http://dx.doi.org/10.1093/eurjhf/hft052] [PMID: 23563576]
[8]
Colucci, W.S.; Elkayam, U.; Horton, D.P.; Abraham, W.T.; Bourge, R.C.; Johnson, A.D.; Wagoner, L.E.; Givertz, M.M.; Liang, C.S.; Neibaur, M.; Haught, W.H.; LeJemtel, T.H. Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N. Engl. J. Med., 2000, 343(4), 246-253.
[http://dx.doi.org/10.1056/NEJM200007273430403] [PMID: 10911006]
[9]
Kostis, J.B.; Packer, M.; Black, H.R.; Schmieder, R.; Henry, D.; Levy, E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am. J. Hypertens., 2004, 17(2), 103-111.
[http://dx.doi.org/10.1016/j.amjhyper.2003.09.014] [PMID: 14751650]
[10]
McMurray, J.J.; Packer, M.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.L.; Shi, V.C.; Solomon, S.D.; Swedberg, K.; Zile, M.R. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med., 2014, 371(11), 993-1004.
[http://dx.doi.org/10.1056/NEJMoa1409077] [PMID: 25176015]
[11]
Yancy, C.W.; Jessup, M.; Bozkurt, B.; Butler, J.; Casey, D.E., Jr; Colvin, M.M.; Drazner, M.H.; Filippatos, G.; Fonarow, G.C.; Givertz, M.M.; Hollenberg, S.M.; Lindenfeld, J.; Masoudi, F.A.; McBride, P.E.; Peterson, P.N.; Stevenson, L.W.; Westlake, C. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. J. Am. Coll. Cardiol., 2016, 68(13), 1476-1488.
[http://dx.doi.org/10.1016/j.jacc.2016.05.011] [PMID: 27216111]
[12]
Packer, M.; McMurray, J.J.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.L.; Shi, V.C.; Solomon, S.D.; Swedberg, K.; Zile, M.; Andersen, K.; Arango, J.L.; Arnold, J.M.; Bělohlávek, J.; Böhm, M.; Boytsov, S.; Burgess, L.J.; Cabrera, W.; Calvo, C.; Chen, C.H.; Dukat, A.; Duarte, Y.C.; Erglis, A.; Fu, M.; Gomez, E.; Gonzàlez-Medina, A.; Hagège, A.A.; Huang, J.; Katova, T.; Kiatchoosakun, S.; Kim, K.S.; Kozan, Ö.; Llamas, E.B.; Martinez, F.; Merkely, B.; Mendoza, I.; Mosterd, A.; Negrusz-Kawecka, M.; Peuhkurinen, K.; Ramires, F.J.; Refsgaard, J.; Rosenthal, A.; Senni, M.; Sibulo, A.S., Jr; Silva-Cardoso, J.; Squire, I.B.; Starling, R.C.; Teerlink, J.R.; Vanhaecke, J.; Vinereanu, D.; Wong, R.C. PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation, 2015, 131(1), 54-61.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013748] [PMID: 25403646]
[13]
McMurray, J.; Packer, M.; Desai, A.; Gong, J.; Greenlaw, N.; Lefkowitz, M.; Rizkala, A.; Shi, V.; Rouleau, J.; Solomon, S.; Swedberg, K.; Zile, M.R.; Andersen, K.; Arango, J.L.; Arnold, M.; Bĕlohlávek, J.; Böhm, M.; Boytsov, S.; Burgess, L.; Cabrera, W.; Chen, C.H.; Erglis, A.; Fu, M.; Gomez, E.; Gonzalez, A.; Hagege, A.A.; Katova, T.; Kiatchoosakun, S.; Kim, K.S.; Bayram, E.; Martinez, F.; Merkely, B.; Mendoza, I.; Mosterd, A.; Negrusz-Kawecka, M.; Peuhkurinen, K.; Ramires, F.; Refsgaard, J.; Senni, M.; Sibulo, A.S., Jr; Silva-Cardoso, J.; Squire, I.; Starling, R.C.; Vinereanu, D.; Teerlink, J.R.; Wong, R. PARADIGM-HF Committees and Investigators. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur. Heart J., 2015, 36(7), 434-439.
[http://dx.doi.org/10.1093/eurheartj/ehu455] [PMID: 25416329]
[14]
Cohn, J.N.; Levine, T.B.; Olivari, M.T.; Garberg, V.; Lura, D.; Francis, G.S.; Simon, A.B.; Rector, T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med., 1984, 311(13), 819-823.
[http://dx.doi.org/10.1056/NEJM198409273111303] [PMID: 6382011]
[15]
Dobre, D.; Borer, J.S.; Fox, K.; Swedberg, K.; Adams, K.F.; Cleland, J.G.; Cohen-Solal, A.; Gheorghiade, M.; Gueyffier, F.; O’Connor, C.M.; Fiuzat, M.; Patak, A.; Piña, I.L.; Rosano, G.; Sabbah, H.N.; Tavazzi, L.; Zannad, F. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. Eur. J. Heart Fail., 2014, 16(1), 76-85.
[http://dx.doi.org/10.1093/eurjhf/hft129] [PMID: 23928650]
[16]
Swedberg, K.; Komajda, M.; Böhm, M.; Borer, J.S.; Ford, I.; Dubost-Brama, A.; Lerebours, G.; Tavazzi, L. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet, 2010, 376(9744), 875-885.
[http://dx.doi.org/10.1016/S0140-6736(10)61198-1] [PMID: 20801500]
[17]
Böhm, M.; Swedberg, K.; Komajda, M.; Borer, J.S.; Ford, I.; Dubost-Brama, A.; Lerebours, G.; Tavazzi, L. SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet, 2010, 376(9744), 886-894.
[http://dx.doi.org/10.1016/S0140-6736(10)61259-7] [PMID: 20801495]
[18]
Böhm, M.; Borer, J.; Ford, I.; Gonzalez-Juanatey, J.R.; Komajda, M.; Lopez-Sendon, J.; Reil, J.C.; Swedberg, K.; Tavazzi, L. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin. Res. Cardiol., 2013, 102(1), 11-22.
[http://dx.doi.org/10.1007/s00392-012-0467-8] [PMID: 22575988]
[19]
Teerlink, J.R. Ivabradine in heart failure-no paradigm SHIF yet. Lancet, 2010, 376(9744), 847-849.
[http://dx.doi.org/10.1016/S0140-6736(10)61314-1] [PMID: 20801501]
[20]
Martin, R.I.; Pogoryelova, O.; Koref, M.S.; Bourke, J.P.; Teare, M.D.; Keavney, B.D. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart, 2014, 100(19), 1506-1510.
[http://dx.doi.org/10.1136/heartjnl-2014-305482] [PMID: 24951486]
[21]
Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Inzucchi, S.E. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 2015, 373(22), 2117-2128.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[22]
Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med., 2017, 377(7), 644-657.
[http://dx.doi.org/10.1056/NEJMoa1611925] [PMID: 28605608]
[23]
Fitchett, D.; Butler, J.; van de Borne, P.; Zinman, B.; Lachin, J.M.; Wanner, C.; Woerle, H.J.; Hantel, S.; George, J.T.; Johansen, O.E.; Inzucchi, S.E. EMPA-REG OUTCOME® trial investigators. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur. Heart J., 2018, 39(5), 363-370.
[http://dx.doi.org/10.1093/eurheartj/ehx511] [PMID: 29020355]
[24]
Fitchett, D.; Inzucchi, S.E.; Cannon, C.P.; McGuire, D.K.; Scirica, B.M.; Johansen, O.E.; Sambevski, S.; Kaspers, S.; Pfarr, E.; George, J.T.; Zinman, B. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation, 2019, 139(11), 1384-1395.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037778] [PMID: 30586757]
[25]
Inzucchi, S.E.; Kosiborod, M.; Fitchett, D.; Wanner, C.; Hehnke, U.; Kaspers, S.; George, J.T.; Zinman, B. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation, 2018, 138(17), 1904-1907.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035759] [PMID: 30354665]
[26]
Hasenfuss, G.; Teerlink, J.R. Cardiac inotropes: current agents and future directions. Eur. Heart J., 2011, 32(15), 1838-1845.
[http://dx.doi.org/10.1093/eurheartj/ehr026] [PMID: 21388993]
[27]
Malik, F.I.; Hartman, J.J.; Elias, K.A.; Morgan, B.P.; Rodriguez, H.; Brejc, K.; Anderson, R.L.; Sueoka, S.H.; Lee, K.H.; Finer, J.T.; Sakowicz, R.; Baliga, R.; Cox, D.R.; Garard, M.; Godinez, G.; Kawas, R.; Kraynack, E.; Lenzi, D.; Lu, P.P.; Muci, A.; Niu, C.; Qian, X.; Pierce, D.W.; Pokrovskii, M.; Suehiro, I.; Sylvester, S.; Tochimoto, T.; Valdez, C.; Wang, W.; Katori, T.; Kass, D.A.; Shen, Y.T.; Vatner, S.F.; Morgans, D.J. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science, 2011, 331(6023), 1439-1443.
[http://dx.doi.org/10.1126/science.1200113] [PMID: 21415352]
[28]
Teerlink, J.R.; Clarke, C.P.; Saikali, K.G.; Lee, J.H.; Chen, M.M.; Escandon, R.D.; Elliott, L.; Bee, R.; Habibzadeh, M.R.; Goldman, J.H.; Schiller, N.B.; Malik, F.I.; Wolff, A.A. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet, 2011, 378(9792), 667-675.
[http://dx.doi.org/10.1016/S0140-6736(11)61219-1] [PMID: 21856480]
[29]
Cleland, J.G.F.; Teerlink, J.R.; Senior, R.; Nifontov, E.M.; Mc Murray, J.J.; Lang, C.C.; Tsyrlin, V.A.; Greenberg, B.H.; Mayet, J.; Francis, D.P.; Shaburishvili, T.; Monaghan, M.; Saltzberg, M.; Neyses, L.; Wasserman, S.M.; Lee, J.H.; Saikali, K.G.; Clarke, C.P.; Goldman, J.H.; Wolff, A.A.; Malik, F.I. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet, 2011, 378(9792), 676-683.
[http://dx.doi.org/10.1016/S0140-6736(11)61126-4] [PMID: 21856481]
[30]
Teerlink, J.R.; Felker, G.M.; McMurray, J.J.; Solomon, S.D.; Adams, K.F., Jr; Cleland, J.G.; Ezekowitz, J.A.; Goudev, A.; Macdonald, P.; Metra, M.; Mitrovic, V.; Ponikowski, P.; Serpytis, P.; Spinar, J.; Tomcsányi, J.; Vandekerckhove, H.J.; Voors, A.A.; Monsalvo, M.L.; Johnston, J.; Malik, F.I.; Honarpour, N. COSMIC-HF Investigators. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet, 2016, 388(10062), 2895-2903.
[http://dx.doi.org/10.1016/S0140-6736(16)32049-9] [PMID: 27914656]
[31]
Teerlink, J.R.; Felker, G.M.; McMurray, J.J.V.; Ponikowski, P.; Metra, M.; Filippatos, G.S.; Ezekowitz, J.A.; Dickstein, K.; Cleland, J.G.F.; Kim, J.B.; Lei, L.; Knusel, B.; Wolff, A.A.; Malik, F.I.; Wasserman, S.M. ATOMIC-AHF Investigators. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF Study. J. Am. Coll. Cardiol., 2016, 67(12), 1444-1455.
[http://dx.doi.org/10.1016/j.jacc.2016.01.031] [PMID: 27012405]
[32]
Greene, S.J.; Gheorghiade, M.; Borlaug, B.A.; Pieske, B.; Vaduganathan, M.; Burnett, J.C., Jr; Roessig, L.; Stasch, J.P.; Solomon, S.D.; Paulus, W.J.; Butler, J. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J. Am. Heart Assoc., 2013, 2(6) e000536
[http://dx.doi.org/10.1161/JAHA.113.000536] [PMID: 24334823]
[33]
Marti, C.N.; Gheorghiade, M.; Kalogeropoulos, A.P.; Georgiopoulou, V.V.; Quyyumi, A.A.; Butler, J. Endothelial dysfunction, arterial stiffness, and heart failure. J. Am. Coll. Cardiol., 2012, 60(16), 1455-1469.
[http://dx.doi.org/10.1016/j.jacc.2011.11.082] [PMID: 22999723]
[34]
Gheorghiade, M.; Greene, S.J.; Butler, J.; Filippatos, G.; Lam, C.S.; Maggioni, A.P.; Ponikowski, P.; Shah, S.J.; Solomon, S.D.; Kraigher-Krainer, E.; Samano, E.T.; Müller, K.; Roessig, L.; Pieske, B. . SOCRATES-REDUCED Investigators and Coordinators. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA, 2015, 314(21), 2251-2262.
[http://dx.doi.org/10.1001/jama.2015.15734] [PMID: 26547357]
[35]
Pieske, B.; Maggioni, A.P.; Lam, C.S.P.; Pieske-Kraigher, E.; Filippatos, G.; Butler, J.; Ponikowski, P.; Shah, S.J.; Solomon, S.D.; Scalise, A.V.; Mueller, K.; Roessig, L.; Gheorghiade, M. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heart failure patients with preserved ef (SOCRATES-PRESERVED)study. Eur. Heart J., 2017, 38(15), 1119-1127.
[http://dx.doi.org/10.1093/eurheartj/ehw593] [PMID: 28369340]
[36]
Bramlage, P.; Swift, S.L.; Thoenes, M.; Minguet, J.; Ferrero, C.; Schmieder, R.E. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur. J. Heart Fail., 2016, 18(1), 28-37.
[http://dx.doi.org/10.1002/ejhf.444] [PMID: 26634965]
[37]
Kolkhof, P.; Delbeck, M.; Kretschmer, A.; Steinke, W.; Hartmann, E.; Bärfacker, L.; Eitner, F.; Albrecht-Küpper, B.; Schäfer, S. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovasc. Pharmacol., 2014, 64(1), 69-78.
[http://dx.doi.org/10.1097/FJC.0000000000000091] [PMID: 24621652]
[38]
Pitt, B.; Kober, L.; Ponikowski, P.; Gheorghiade, M.; Filippatos, G.; Krum, H.; Nowack, C.; Kolkhof, P.; Kim, S.Y.; Zannad, F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J., 2013, 34(31), 2453-2463.
[http://dx.doi.org/10.1093/eurheartj/eht187] [PMID: 23713082]
[39]
Filippatos, G.; Anker, S.D.; Böhm, M.; Gheorghiade, M.; Køber, L.; Krum, H.; Maggioni, A.P.; Ponikowski, P.; Voors, A.A.; Zannad, F.; Kim, S.Y.; Nowack, C.; Palombo, G.; Kolkhof, P.; Kimmeskamp-Kirschbaum, N.; Pieper, A.; Pitt, B. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur. Heart J., 2016, 37(27), 2105-2114.
[http://dx.doi.org/10.1093/eurheartj/ehw132] [PMID: 27130705]
[40]
Slaughter, M.S.; Rogers, J.G.; Milano, C.A.; Russell, S.D.; Conte, J.V.; Feldman, D.; Sun, B.; Tatooles, A.J.; Delgado, R.M., III; Long, J.W.; Wozniak, T.C.; Ghumman, W.; Farrar, D.J.; Frazier, O.H. HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N. Engl. J. Med., 2009, 361(23), 2241-2251.
[http://dx.doi.org/10.1056/NEJMoa0909938] [PMID: 19920051]
[41]
Miller, L.W.; Pagani, F.D.; Russell, S.D.; John, R.; Boyle, A.J.; Aaronson, K.D.; Conte, J.V.; Naka, Y.; Mancini, D.; Delgado, R.M.; MacGillivray, T.E.; Farrar, D.J.; Frazier, O.H. HeartMate II Clinical Investigators. Use of a continuous-flow device in patients awaiting heart transplantation. N. Engl. J. Med., 2007, 357(9), 885-896.
[http://dx.doi.org/10.1056/NEJMoa067758] [PMID: 17761592]
[42]
Rogers, J.G.; Aaronson, K.D.; Boyle, A.J.; Russell, S.D.; Milano, C.A.; Pagani, F.D.; Edwards, B.S.; Park, S.; John, R.; Conte, J.V.; Farrar, D.J.; Slaughter, M.S. HeartMate II Investigators. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J. Am. Coll. Cardiol., 2010, 55(17), 1826-1834.
[http://dx.doi.org/10.1016/j.jacc.2009.12.052] [PMID: 20413033]
[43]
Rogers, J.G.; Pagani, F.D.; Tatooles, A.J.; Bhat, G.; Slaughter, M.S.; Birks, E.J.; Boyce, S.W.; Najjar, S.S.; Jeevanandam, V.; Anderson, A.S.; Gregoric, I.D.; Mallidi, H.; Leadley, K.; Aaronson, K.D.; Frazier, O.H.; Milano, C.A. Intrapericardial left ventricular assist device for advanced heart failure. N. Engl. J. Med., 2017, 376(5), 451-460.
[http://dx.doi.org/10.1056/NEJMoa1602954] [PMID: 28146651]
[44]
Pagani, F.D.; Miller, L.W.; Russell, S.D.; Aaronson, K.D.; John, R.; Boyle, A.J.; Conte, J.V.; Bogaev, R.C.; MacGillivray, T.E.; Naka, Y.; Mancini, D.; Massey, H.T.; Chen, L.; Klodell, C.T.; Aranda, J.M.; Moazami, N.; Ewald, G.A.; Farrar, D.J.; Frazier, O.H. HeartMate II Investigators. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J. Am. Coll. Cardiol., 2009, 54(4), 312-321.
[http://dx.doi.org/10.1016/j.jacc.2009.03.055] [PMID: 19608028]
[45]
Birks, E.J.; George, R.S.; Hedger, M.; Bahrami, T.; Wilton, P.; Bowles, C.T.; Webb, C.; Bougard, R.; Amrani, M.; Yacoub, M.H.; Dreyfus, G.; Khaghani, A. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation, 2011, 123(4), 381-390.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.933960] [PMID: 21242487]
[46]
Drakos, S.G.; Kfoury, A.G.; Stehlik, J.; Selzman, C.H.; Reid, B.B.; Terrovitis, J.V.; Nanas, J.N.; Li, D.Y. Bridge to recovery: understanding the disconnect between clinical and biological outcomes. Circulation, 2012, 126(2), 230-241.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.040261] [PMID: 22777666]
[47]
Kirklin, J.K.; Naftel, D.C.; Pagani, F.D.; Kormos, R.L.; Stevenson, L.W.; Blume, E.D.; Myers, S.L.; Miller, M.A.; Baldwin, J.T.; Young, J.B. Seventh INTERMACS annual report: 15,000 patients and counting. J. Heart Lung Transplant., 2015, 34(12), 1495-1504.
[http://dx.doi.org/10.1016/j.healun.2015.10.003] [PMID: 26520247]
[48]
Kirklin, J.K.; Naftel, D.C.; Stevenson, L.W.; Kormos, R.L.; Pagani, F.D.; Miller, M.A.; Ulisney, K.; Young, J.B. INTERMACS database for durable devices for circulatory support: first annual report. J. Heart Lung Transplant., 2008, 27(10), 1065-1072.
[http://dx.doi.org/10.1016/j.healun.2008.07.021] [PMID: 18926395]
[49]
Kirklin, J.K.; Naftel, D.C. Mechanical circulatory support: registering a therapy in evolution. Circ Heart Fail, 2008, 1(3), 200-205.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.108.782599] [PMID: 19808290]
[50]
Stevenson, L.W.; Couper, G. On the fledgling field of mechanical circulatory support. J. Am. Coll. Cardiol., 2007, 50(8), 748-751.
[http://dx.doi.org/10.1016/j.jacc.2007.04.071] [PMID: 17707179]
[51]
Park, S.J.; Milano, C.A.; Tatooles, A.J.; Rogers, J.G.; Adamson, R.M.; Steidley, D.E.; Ewald, G.A.; Sundareswaran, K.S.; Farrar, D.J.; Slaughter, M.S. HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail, 2012, 5(2), 241-248.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.111.963991] [PMID: 22282104]
[52]
Mehra, M.R. The burden of haemocompatibility with left ventricular assist systems: a complex weave. Eur. Heart J., 2019, 40(8), 673-677.
[http://dx.doi.org/10.1093/eurheartj/ehx036] [PMID: 28329374]
[53]
Kirsch, M.; Vermes, E.; Damy, T.; Nakashima, K.; Sénéchal, M.; Boval, B.; Drouet, L.; Loisance, D. Single-centre experience with the Thoratec paracorporeal ventricular assist device for patients with primary cardiac failure. Arch. Cardiovasc. Dis., 2009, 102(6-7), 509-518.
[http://dx.doi.org/10.1016/j.acvd.2009.03.010] [PMID: 19664570]
[54]
Wheeldon, D.R.; LaForge, D.H.; Lee, J.; Jansen, P.G.; Jassawalla, J.S.; Portner, P.M. Novacor left ventricular assist system long-term performance: comparison of clinical experience with demonstrated in vitro reliability. ASAIO J., 2002, 48(5), 546-551.
[http://dx.doi.org/10.1097/00002480-200209000-00018] [PMID: 12296577]
[55]
Rose, E.A.; Gelijns, A.C.; Moskowitz, A.J.; Heitjan, D.F.; Stevenson, L.W.; Dembitsky, W.; Long, J.W.; Ascheim, D.D.; Tierney, A.R.; Levitan, R.G.; Watson, J.T.; Meier, P.; Ronan, N.S.; Shapiro, P.A.; Lazar, R.M.; Miller, L.W.; Gupta, L.; Frazier, O.H.; Desvigne-Nickens, P.; Oz, M.C.; Poirier, V.L. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med., 2001, 345(20), 1435-1443.
[http://dx.doi.org/10.1056/NEJMoa012175] [PMID: 11794191]
[56]
Rogers, J.G.; Butler, J.; Lansman, S.L.; Gass, A.; Portner, P.M.; Pasque, M.K.; Pierson, R.N., III; Investigators, I.N. INTrEPID Investigators. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J. Am. Coll. Cardiol., 2007, 50(8), 741-747.
[http://dx.doi.org/10.1016/j.jacc.2007.03.063] [PMID: 17707178]
[57]
Copeland, J.G.; Smith, R.G.; Arabia, F.A.; Nolan, P.E.; Sethi, G.K.; Tsau, P.H.; McClellan, D.; Slepian, M.J. CardioWest Total Artificial Heart Investigators. Cardiac replacement with a total artificial heart as a bridge to transplantation. N. Engl. J. Med., 2004, 351(9), 859-867.
[http://dx.doi.org/10.1056/NEJMoa040186] [PMID: 15329423]
[58]
Aaronson, K.D.; Slaughter, M.S.; Miller, L.W.; McGee, E.C.; Cotts, W.G.; Acker, M.A.; Jessup, M.L.; Gregoric, I.D.; Loyalka, P.; Frazier, O.H.; Jeevanandam, V.; Anderson, A.S.; Kormos, R.L.; Teuteberg, J.J.; Levy, W.C.; Naftel, D.C.; Bittman, R.M.; Pagani, F.D.; Hathaway, D.R.; Boyce, S.W. HeartWare Ventricular Assist Device (HVAD) Bridge to Transplant ADVANCE Trial Investigators. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation, 2012, 125(25), 3191-3200.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.058412] [PMID: 22619284]
[59]
Jorde, U.P.; Kushwaha, S.S.; Tatooles, A.J.; Naka, Y.; Bhat, G.; Long, J.W.; Horstmanshof, D.A.; Kormos, R.L.; Teuteberg, J.J.; Slaughter, M.S.; Birks, E.J.; Farrar, D.J.; Park, S.J. HeartMate II Clinical Investigators. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J. Am. Coll. Cardiol., 2014, 63(17), 1751-1757.
[http://dx.doi.org/10.1016/j.jacc.2014.01.053] [PMID: 24613333]
[60]
Mehra, M.R.; Naka, Y.; Uriel, N.; Goldstein, D.J.; Cleveland, J.C., Jr; Colombo, P.C.; Walsh, M.N.; Milano, C.A.; Patel, C.B.; Jorde, U.P.; Pagani, F.D.; Aaronson, K.D.; Dean, D.A.; McCants, K.; Itoh, A.; Ewald, G.A.; Horstmanshof, D.; Long, J.W.; Salerno, C.; Investigators, M. MOMENTUM 3 Investigators. A fully magnetically levitated circulatory pump for advanced heart failure. N. Engl. J. Med., 2017, 376(5), 440-450.
[http://dx.doi.org/10.1056/NEJMoa1610426] [PMID: 27959709]
[61]
Estep, J.D.; Starling, R.C.; Horstmanshof, D.A.; Milano, C.A.; Selzman, C.H.; Shah, K.B.; Loebe, M.; Moazami, N.; Long, J.W.; Stehlik, J.; Kasirajan, V.; Haas, D.C.; O’Connell, J.B.; Boyle, A.J.; Farrar, D.J.; Rogers, J.G.; Investigators, R.S. ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. J. Am. Coll. Cardiol., 2015, 66(16), 1747-1761.
[http://dx.doi.org/10.1016/j.jacc.2015.07.075] [PMID: 26483097]
[62]
Shah, K.B.; Starling, R.C.; Rogers, J.G.; Horstmanshof, D.A.; Long, J.W.; Kasirajan, V.; Stehlik, J.; Chuang, J.; Farrar, D.J.; Estep, J.D. ROADMAP Investigators. Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study. J. Heart Lung Transplant., 2018, 37(6), 706-714.
[http://dx.doi.org/10.1016/j.healun.2017.12.003] [PMID: 29275844]
[63]
Thiele, H.; Zeymer, U.; Neumann, F.J.; Ferenc, M.; Olbrich, H.G.; Hausleiter, J.; Richardt, G.; Hennersdorf, M.; Empen, K.; Fuernau, G.; Desch, S.; Eitel, I.; Hambrecht, R.; Fuhrmann, J.; Böhm, M.; Ebelt, H.; Schneider, S.; Schuler, G.; Werdan, K. IABP-SHOCK II Trial Investigators. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N. Engl. J. Med., 2012, 367(14), 1287-1296.
[http://dx.doi.org/10.1056/NEJMoa1208410] [PMID: 22920912]
[64]
Thiele, H.; Zeymer, U.; Neumann, F.J.; Ferenc, M.; Olbrich, H.G.; Hausleiter, J.; de Waha, A.; Richardt, G.; Hennersdorf, M.; Empen, K.; Fuernau, G.; Desch, S.; Eitel, I.; Hambrecht, R.; Lauer, B.; Böhm, M.; Ebelt, H.; Schneider, S.; Werdan, K.; Schuler, G. Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) trial investigators. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet, 2013, 382(9905), 1638-1645.
[http://dx.doi.org/10.1016/S0140-6736(13)61783-3] [PMID: 24011548]
[65]
Unverzagt, S.; Buerke, M.; de Waha, A.; Haerting, J.; Pietzner, D.; Seyfarth, M.; Thiele, H.; Werdan, K.; Zeymer, U.; Prondzinsky, R. Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst. Rev., 2015, 27(3) CD007398
[http://dx.doi.org/10.1002/14651858.CD007398.pub3] [PMID: 25812932]
[66]
Seyfarth, M.; Sibbing, D.; Bauer, I.; Fröhlich, G.; Bott-Flügel, L.; Byrne, R.; Dirschinger, J.; Kastrati, A.; Schömig, A. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J. Am. Coll. Cardiol., 2008, 52(19), 1584-1588.
[http://dx.doi.org/10.1016/j.jacc.2008.05.065] [PMID: 19007597]
[67]
Ouweneel, D.M.; Eriksen, E.; Sjauw, K.D.; van Dongen, I.M.; Hirsch, A.; Packer, E.J.; Vis, M.; Wykrzykowska, J.J.; Koch, K.T.; Baan, J.; de Winter, R.J.; Piek, J.J.; Lagrand, W.L.; de Mol, B.A.; Tijssen, J.G.; Henriques, J.P. Impella CP versus intra-aortic balloon pump support in acute myocardial infarction complicated by cardiogenic shock. The IMPRESS in severe shock trial. J. Am. Coll. Cardiol., 2017, 69, 278-287.
[http://dx.doi.org/10.1016/j.jacc.2016.10.022] [PMID: 27810347]
[68]
O’Neill, W.W.; Kleiman, N.S.; Moses, J.; Henriques, J.P.; Dixon, S.; Massaro, J.; Palacios, I.; Maini, B.; Mulukutla, S.; Dzavík, V.; Popma, J.; Douglas, P.S.; Ohman, M. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation, 2012, 126(14), 1717-1727.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.098194] [PMID: 22935569]
[69]
Thiele, H.; Jobs, A.; Ouweneel, D.M.; Henriques, J.P.S.; Seyfarth, M.; Desch, S.; Eitel, I.; Pöss, J.; Fuernau, G.; de Waha, S. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur. Heart J., 2017, 38(47), 3523-3531.
[http://dx.doi.org/10.1093/eurheartj/ehx363] [PMID: 29020341]
[70]
Thiagarajan, R.R.; Barbaro, R.P.; Rycus, P.T.; Mcmullan, D.M.; Conrad, S.A.; Fortenberry, J.D.; Paden, M.L. ELSO member centers. Extracorporeal life support organization registry international report 2016. ASAIO J., 2017, 63(1), 60-67.
[http://dx.doi.org/10.1097/MAT.0000000000000475] [PMID: 27984321]
[71]
Mazzeffi, M.; Greenwood, J.; Tanaka, K.; Menaker, J.; Rector, R.; Herr, D.; Kon, Z.; Lee, J.; Griffith, B.; Rajagopal, K.; Pham, S. Bleeding, transfusion, and mortality on extracorporeal life support: ECLS working group on thrombosis and hemostasis. Ann. Thorac. Surg., 2016, 101(2), 682-689.
[http://dx.doi.org/10.1016/j.athoracsur.2015.07.046] [PMID: 26443879]
[72]
Slaughter, M.S.; Pagani, F.D.; Rogers, J.G.; Miller, L.W.; Sun, B.; Russell, S.D.; Starling, R.C.; Chen, L.; Boyle, A.J.; Chillcott, S.; Adamson, R.M.; Blood, M.S.; Camacho, M.T.; Idrissi, K.A.; Petty, M.; Sobieski, M.; Wright, S.; Myers, T.J.; Farrar, D.J. HeartMate II Clinical Investigators. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J. Heart Lung Transplant., 2010, 29(4)(Suppl.), S1-S39.
[http://dx.doi.org/10.1016/j.healun.2010.01.011] [PMID: 20181499]
[73]
Anderson, M.; Morris, D.L.; Tang, D.; Batsides, G.; Kirtane, A.; Hanson, I.; Meraj, P.; Kapur, N.K.; O’Neill, W. Outcomes of patients with right ventricular failure requiring short-term hemodynamic support with the Impella RP device. J. Heart Lung Transplant., 2018, 37(12), 1448-1458.
[http://dx.doi.org/10.1016/j.healun.2018.08.001] [PMID: 30241890]
[74]
Aggarwal, V.; Einhorn, B.N.; Cohen, H.A. Current status of percutaneous right ventricular assist devices: First-in-man use of a novel dual lumen cannula. Catheter. Cardiovasc. Interv., 2016, 88(3), 390-396.
[http://dx.doi.org/10.1002/ccd.26348] [PMID: 26895620]
[75]
Samak, M.; Fatullayev, J.; Sabashnikov, A.; Zeriouh, M.; Rahmanian, P.B.; Choi, Y.H.; Wippermann, J.; Wahlers, T.; Schmack, B.; Ruhparwar, A.; Dohmen, P.M.; Karck, M.; Popov, A.F.; Simon, A.R.; Weymann, A. Past and present of total artificial heart therapy: a success story. Med. Sci. Monit. Basic Res., 2015, 21, 183-190.
[http://dx.doi.org/10.12659/MSMBR.895418] [PMID: 26343363]
[76]
Ozbaran, M.; Yagdi, T.; Engin, C.; Erkul, S.; Balcioglu, O.; Baysal, B.; Nalbantgil, S.; Ertugay, S. Long-term paracorporeal ventricular support systems: a single-center experience. Transplant. Proc., 2013, 45(3), 1013-1016.
[http://dx.doi.org/10.1016/j.transproceed.2013.02.073] [PMID: 23622611]
[77]
Krabatsch, T.; Potapov, E.; Stepanenko, A.; Schweiger, M.; Kukucka, M.; Huebler, M.; Hennig, E.; Hetzer, R. Biventricular circulatory support with two miniaturized implantable assist devices. Circulation, 2011, 124(11)(Suppl.), S179-S186.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.011502] [PMID: 21911810]

Rights & Permissions Print Cite
Article Metrics
27
© 2024 Bentham Science Publishers | Privacy Policy